Treatment of YAC128 mice and their wild‐type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Neurochemistry

• Publication date

  2005-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1471-4159.2005.03255.xPMID 15992377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate‐independent mechanisms

  2005cited by this paper
• Mechanism for the inhibition of transglutaminase 2 by cystamine.

  2005cited by this paper
• Mutant Huntingtin Protein: A Substrate for Transglutaminase 1, 2, and 3

  2005cited by this paper
• Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

  2004cited by this paper
• Brain antioxidant systems in human methamphetamine users

  2004cited by this paper
• Caspase‐mediated proteolysis of the polyglutamine disease protein ataxin‐3

  2004cited by this paper
• Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation

  2004influential reference
• The Energetics of Huntington's Disease

  2004cited by this paper
• Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats

  2004cited by this paper
• Calmodulin Regulates Transglutaminase 2 Cross-Linking of Huntingtin

  2004cited by this paper
• Cystamine Inhibits Caspase Activity

  2003influential reference
• Transglutaminase Cross‐Links in Intranuclear Inclusions in Huntington Disease

  2003cited by this paper
• Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine

  2003cited by this paper
• Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

  2003cited by this paper
• Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor.

  2003cited by this paper
• Huntingtin aggregation and toxicity in Huntington's disease.

  2003cited by this paper
• Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

  2002cited by this paper
• Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?

  2002cited by this paper
• ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease

  2002cited by this paper
• Difference in disease-free survival curve and regional distribution according to subtype of spinocerebellar ataxia: a study of 1,286 Japanese patients.

  2002cited by this paper
• Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways

  2002cited by this paper
• Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease

  2002cited by this paper
• Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease

  2002cited by this paper
• Toxic Proteins in Neurodegenerative Disease

  2002cited by this paper
• Mechanisms for the cytotoxicity of cysteamine.

  2001cited by this paper
• Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide.

  2001cited by this paper
• Kinetics of the reactions of hypochlorous acid and amino acid chloramines with thiols, methionine, and ascorbate.

  2001cited by this paper
• Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease

  2001cited by this paper
• N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.

  2001cited by this paper
• N ε ‐(γ‐l‐Glutamyl)‐l‐lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease

  2001cited by this paper
• Albumin Thiolate Anion Is an Intermediate in the Formation of Albumin-S–S-Homocysteine*

  2001cited by this paper
• Age-associated decline in gamma-glutamylcysteine synthetase gene expression in rats.

  2000cited by this paper
• Protein Crosslinking in Assembly and Remodelling of Extracellular Matrices: The Role of Transglutaminases

  2000influential reference
• Age-associated decline in γ-glutamylcysteine synthetase gene expression in rats

  2000cited by this paper
• Impaired Mitochondrial Function Results in Increased Tissue Transglutaminase Activity In Situ

  2000cited by this paper
• Glutamine repeats and neurodegeneration.

  2000cited by this paper
• Pantetheinase activity of membrane‐bound Vanin‐1: lack of free cysteamine in tissues of Vanin‐1 deficient mice

  2000influential reference
• Increased oxidative damage to DNA in ALS patients.

  2000cited by this paper
• Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

  2000cited by this paper
• Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine

  2000cited by this paper
• Metabolism and functions of glutathione in brain.

  2000influential reference
• Oxidative stress in patients with Friedreich ataxia

  2000cited by this paper
• Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

  2000cited by this paper
• Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.

  1999cited by this paper
• Huntingtin aggregates may not predict neuronal death in Huntington's disease

  1999cited by this paper
• Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

  1999cited by this paper
• The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates.

  1999cited by this paper
• Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide.

  1999cited by this paper
• Biologic and pharmacologic regulation of mammalian glutathione synthesis.

  1999cited by this paper
• Tissue Transglutaminase Is Increased in Huntington's Disease Brain

  1999influential reference
• Differential Expression of Multiple Transglutaminases in Human Brain

  1999cited by this paper
• A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection.

  1999cited by this paper
• Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex.

  1999cited by this paper
• Huntington aggregates may not predict neuronal death in Huntington's disease.

  1999cited by this paper
• Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases.

  1998cited by this paper
• The Effects of Methamphetamine on the Production of Free Radicals and Oxidative Stress 1

  1998cited by this paper
• Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch

  1998cited by this paper
• Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

  1998cited by this paper
• Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.

  1998cited by this paper
• The effects of methamphetamine on the production of free radicals and oxidative stress.

  1998cited by this paper
• S-methylthio-cysteine and cystamine are potent stimulators of thiol production and glutathione synthesis.

  1997cited by this paper
• Polyglutamine Domains Are Substrates of Tissue Transglutaminase: Does Transglutaminase Play a Role in Expanded CAG/Poly‐Q Neurodegenerative Diseases?

  1997cited by this paper
• Validated high-performance liquid chromatography-electrochemical method for determination of glutathione and glutathione disulfide in small tissue samples.

  1997cited by this paper
• The effects of oxidative stress on in vivo brain GSH turnover in young and mature mice.

  1997cited by this paper
• Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system.

  1996cited by this paper
• Putrescine uptake in hamster lung slices and primary cultures of type II pneumocytes.

  1995cited by this paper
• [11] Promotion of cyst(e)ine uptake

  1995influential reference
• Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation.

  1995cited by this paper
• Promotion of cyst(e)ine uptake.

  1995cited by this paper
• Detection and Characterization of a Transport System Mediating Cysteamine Entry into Human Fibroblast Lysosomes

  1995cited by this paper
• Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease

  1994cited by this paper
• Putrescine and paraquat uptake in human lung slices and isolated type II pneumocytes.

  1994cited by this paper
• Kinetics and cellular localisation of putrescine uptake in human lung tissue.

  1993cited by this paper
• Oxidative damage to mitochondrial DNA shows marked age‐dependent increases in human brain

  1993cited by this paper
• Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism.

  1993cited by this paper
• Inactivation of human placenta glutathione S-transferase by SH/SS exchange reaction with biological disulfides.

  1991influential reference
• Competition for polyamine uptake into rat lung slices by WR2721 and analogues.

  1989cited by this paper
• Taurine in the central nervous system and the mammalian actions of taurine.

  1989cited by this paper
• Measurement of cyst(e)amine in physiological samples by high performance liquid chromatography.

  1988cited by this paper
• Effect of Local Injection of Cysteamine and Cystamine on Somatostatin and Neuropeptide Y Levels in the Rat Striatum

  1988cited by this paper
• Mammalian sulfur amino acid metabolism: an overview.

  1987cited by this paper
• Cysteamine and cystamine.

  1987cited by this paper
• Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite.

  1985cited by this paper
• Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Role in therapeutic cystine removal?

  1985cited by this paper
• Huntington's disease

  1984cited by this paper
• Determination of cystamine by high-performance liquid chromatography.

  1984influential reference
• Transglutaminases.

  1984cited by this paper
• Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation.

  1983cited by this paper
• Detection and determination of cysteamine at the nanomole level.

  1983influential reference
• Plasma cysteamine concentrations in children treated for cystinosis.

  1982cited by this paper
• Reversible inactivation of guanylate cyclase by mixed disulfide formation.

  1981cited by this paper
• The role of glutathione turnover in the apparent renal secretion of cystine.

  1981influential reference
• A simple, rapid assay for cysteamine and other thiols.

  1981cited by this paper
• A spectrophotometric method for studying the rates of reaction of disulfides with protein thiol groups applied to bovine serum albumin

  1980cited by this paper
• Glutathione and Ascorbate During Ischemia and Postischemic Reperfusion in Rat Brain

  1980cited by this paper
• Cysteamine, penicillamine, glutathione, and their derivatives analyzed by automated ion exchange column chromatography.

  1978influential reference
• Inhibition of gamma-glutamylcysteine synthetase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria).

  1977cited by this paper
• INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY

  1976cited by this paper
• CHAPTER 1 – Metabolism of Coenzyme A

  1975cited by this paper
• [Species characteristics of cystamine metabolism in mice and rats].

  1974cited by this paper

• The Long Run: A Tribute to Arthur Joseph Lawrence Cooper.

  2025cites this paper
• Cystamine reduces neurodegeneration and epileptogenesis following soman-induced status epilepticus in rats

  2025cites this paper
• Comparative Analysis of Cystamine and Cysteamine as Radioprotectors and Antioxidants: Insights from Monte Carlo Chemical Modeling under High Linear Energy Transfer Radiation and High Dose Rates

  2024cites this paper
• Assessment of Cystamine’s Radioprotective/Antioxidant Ability under High-Dose-Rate Irradiation: A Monte Carlo Multi-Track Chemistry Simulation Study

  2023influential citation
• Effect of Linear Energy Transfer on Cystamine’s Radioprotective Activity: A Study Using the Fricke Dosimeter with 6–500 MeV per Nucleon Carbon Ions—Implication for Carbon Ion Hadrontherapy

  2023cites this paper
• Implications of enigmatic transglutaminase 2 (TG2) in cardiac diseases and therapeutic developments.

  2022cites this paper
• Nrf2 Pathway in Huntington’s Disease (HD): What Is Its Role?

  2022cites this paper
• Cofactors and Coenzymes | Cysteamine

  2021cites this paper
• The Metabolic Importance of the Glutaminase II Pathway in Normal and Cancerous Cells.

  2020cites this paper
• Cystamine and Cysteamine As Inhibitors of Transglutaminases In Vivo

  2020cites this paper
• Ablation of polyamine catabolic enzymes provokes Purkinje cell damage, neuroinflammation, and severe ataxia

  2020cites this paper
• The Metabolic Importance of the Overlooked Asparaginase II Pathway.

  2020cites this paper
• Emerging therapies in Huntington’s disease

  2019cites this paper
• Cysteamine Protects Neurons from Mutant Huntingtin Toxicity

  2019cites this paper
• High Levels of Glutaminase II Pathway Enzymes in Normal and Cancerous Prostate Suggest a Role in ‘Glutamine Addiction’

  2019cites this paper
• Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases

  2019cites this paper
• Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial.

  2019cites this paper
• Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo

  2018cites this paper
• The effects of cysteamine in a mouse model of levodopa-induced dyskinesias.

  2018cites this paper
• Protective effects of cystamine on apoptosis of hippocampal neurons in rats with cerebral ischemia

  2017cites this paper
• Cysteamine prevents vascular leakage through inhibiting transglutaminase in diabetic retina.

  2017cites this paper
• Serotonin as a putative scavenger of hypohalous acid in the brain.

  2016cites this paper
• Reciprocal Control of Thyroid Binding and the Pipecolate Pathway in the Brain

  2016cites this paper
• Transglutaminases and Neurological Diseases

  2015cites this paper
• Cystamine induces AIF-mediated apoptosis through glutathione depletion.

  2015cites this paper
• Role of the Vnn1 pantetheinase in tissue tolerance to stress.

  2014cites this paper
• An in situ measurement of extracellular cysteamine, homocysteine, and cysteine concentrations in organotypic hippocampal slice cultures by integration of electroosmotic sampling and microfluidic analysis.

  2013cites this paper
• Monitering the metabolism of Thiols/disulfides in the extracellular space of organotypic hippocampal slice cultures by online microfluidic analysis coupled with electroosmotic sampling

  2013cites this paper
• Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

  2012cites this paper
• Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice

  2012cites this paper
• Diverse biological activities of the vascular non-inflammatory molecules - the Vanin pantetheinases.

  2012cites this paper
• New mechanistic explanation for the localization of ulcers in the rat duodenum: role of iron and selective uptake of cysteamine.

  2012cites this paper
• Trinucleotide-Expansion Diseases

  2011cites this paper
• Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.

  2011cites this paper
• Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria

  2011cites this paper
• Neuroprotection in Huntington’s Disease

  2011cites this paper
• Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.

  2010cites this paper
• Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.

  2010cites this paper
• Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases

  2010cites this paper
• Aberrant Rab11-Dependent Trafficking of the Neuronal Glutamate Transporter EAAC1 Causes Oxidative Stress and Cell Death in Huntington's Disease

  2010cites this paper
• Effect of hyperoxic resuscitation on propensity of germinal matrix haemorrhage and cerebral injury

  2010cites this paper
• Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.

  2010cites this paper
• Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism.

  2009cites this paper
• Cysteamine in 3- nitropropionic acid model of Huntington's disease in rats: Modulation of mitochondrial function and amino acid pattern

  2009cites this paper
• Transglutaminase activation in neurodegenerative diseases.

  2009cites this paper
• Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease.

  2009cites this paper
• Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits.

  2009cites this paper
• An introduction to methods for analyzing thiols and disulfides: Reactions, reagents, and practical considerations.

  2009cites this paper
• Transglutaminases and neurodegeneration

  2009influential citation
• Cystamine restores GSTA3 levels in Vanin-1 null mice.

  2008cites this paper
• Cystamine prevents haloperidol‐induced decrease of BDNF/TrkB signaling in mouse frontal cortex

  2008cites this paper
• Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: central role of free cysteine and cysteamine.

  2007cites this paper
• A Novel Cell-permeable Antioxidant Peptide, SS31, Attenuates Ischemic Brain Injury by Down-regulating CD36*

  2007cites this paper
• Transglutaminase 2 in neurodegenerative disorders.

  2007cites this paper
• Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.

  2006cites this paper
• CYTE‐I‐HD: Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease

  2006cites this paper
• Update on huntington’s disease

  2006cites this paper
• Cystamine and cysteamine prevent 3‐NP‐induced mitochondrial depolarization of Huntington's disease knock‐in striatal cells

  2006cites this paper
• Characterization and treatment of mouse models of Huntington disease

  2005cites this paper
• Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease

  2005cites this paper
• British Journal of Clinical Pharmacology Pharmacokinetics of Cysteamine Bitartrate following Gastrointestinal Infusion

  year unknowncites this paper